* Neurex Corp., of Menlo Park, Calif., said it completed the first in series of small studies to evaluate the effectiveness of Corlopam (fenoldopam mesylate) for treatment of kidney damage. The company said analysis of the findings is under way. Neurex has a new drug application under review by the FDA for use of Corlopam for blood pressure control.
* The Liposome Co., of Princeton, N.J., said Abelcet, a lipid-based form of amphotericin B, was approved in Spain as a first-line treatment for candidiasis. The drug previously was cleared in Spain as a second-line therapy for systemic fungal infections.